AI assistant
Moleculin Biotech, Inc. — Director's Dealing 2020
Jul 7, 2020
34881_dirs_2020-07-07_183c1a62-ba59-44ce-a2ee-185faaa944d3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2020-07-02
Reporting Person: KLEMP WALTER V (Director, CEO and President)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-07-02 | Stock option (right to buy) | $0.928 | A | 500000 | Acquired | 2030-07-02 | Common Stock (500000.0) | Direct |
| 2020-07-02 | Restricted Stock Units | $ | A | 353211 | Acquired | Common Stock (353211.0) | Direct |
Footnotes
F1: (1) The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F2: (2) Issued in connection with the reporting person's employment with the Company.
F3: (3) Each restricted stock unit represents a contingent right to receive one share of Company common stock.
F4: (4) The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.